olanzapine

Ligand id: 47

Name: olanzapine

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: olanzapine

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 4
Hydrogen bond donors 1
Rotatable bonds 1
Topological polar surface area 59.11
Molecular weight 312.14
XLogP 3.51
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

References
1. Arnt J, Skarsfeldt T. (1998)
Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence.
Neuropsychopharmacology18 (2): 63-101. [PMID:9430133]
2. Herrick-Davis K, Grinde E, Teitler M. (2000)
Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors.
J Pharmacol Exp Ther295: 226-232. [PMID:10991983]
3. Kohen R, Metcalf MA, Khan N, Druck T, Huebner K, Lachowicz JE, Meltzer HY, Sibley DR, Roth BL, Hamblin MW. (1996)
Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor.
J Neurochem66: 47-56. [PMID:8522988]
4. Kongsamut S, Kang J, Chen XL, Roehr J, Rampe D. (2002)
A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs.
Eur J Pharmacol450: 37-41. [PMID:12176106]
5. Kongsamut S, Roehr JE, Cai J, Hartman HB, Weissensee P, Kerman LL, Tang L, Sandrasagra A. (1996)
Iloperidone binding to human and rat dopamine and 5-HT receptors.
Eur J Pharmacol317: 417-423. [PMID:8997630]
6. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, Jayathilake K, Meltzer HY, Roth BL. (2003)
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.
Neuropsychopharmacology28: 519-526. [PMID:12629531]
7. Newman-Tancredi A, Gavaudan S, Conte C, Chaput C, Touzard M, Verriele L, Audinot V, Millan MJ. (1998)
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.
Eur J Pharmacol355: 245-256. [PMID:9760039]
8. Nourian Z, Mow T, Muftic D, Burek S, Pedersen ML, Matz J, Mulvany MJ. (2008)
Orthostatic hypotensive effect of antipsychotic drugs in Wistar rats by in vivo and in vitro studies of alpha1-adrenoceptor function.
Psychopharmacology (Berl.)199 (1): 15-27. [PMID:18542932]
9. Purohit A, Smith C, Herrick-Davis K, Teitler M. (2005)
Stable expression of constitutively activated mutant h5HT6 and h5HT7 serotonin receptors: inverse agonist activity of antipsychotic drugs.
Psychopharmacology (Berl)179: 461-469. [PMID:15821958]
10. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ, Shen Y, Meltzer HY, Sibley DR. (1994)
Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors.
J Pharmacol Exp Ther268: 1403-1410. [PMID:7908055]
11. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE. (1996)
Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.
Psychopharmacology (Berl)124: 57-73. [PMID:8935801]
12. Shahid M, Walker GB, Zorn SH, Wong EH. (2009)
Asenapine: a novel psychopharmacologic agent with a unique human receptor signature.
J. Psychopharmacol. (Oxford)23 (1): 65-73. [PMID:18308814]
13. Thomas DR, Gittins SA, Collin LL, Middlemiss DN, Riley G, Hagan J, Gloger I, Ellis CE, Forbes IT, Brown AM. (1998)
Functional characterisation of the human cloned 5-HT7 receptor (long form); antagonist profile of SB-258719.
Br J Pharmacol124: 1300-1306. [PMID:9720804]